myelofibrosis

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

News

Lilly's M&A team strikes again with $2.3bn Ajax takeover

With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.

News

Karyopharm eyes Xpovio filing in myelofibrosis on mixed data

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.

News

Novartis sheds MorphoSys staff, sites after pelabresib delay

Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.

News

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or

News

MorphoSys shrugs off mixed results for myelofibrosis drug

MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial.

Ipsen charts $1.75bn course for Kartos acquisition

Lilly's M&A team strikes again with $2.3bn Ajax takeover

Karyopharm eyes Xpovio filing in myelofibrosis on mixed data

Novartis sheds MorphoSys staff, sites after pelabresib delay

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

MorphoSys shrugs off mixed results for myelofibrosis drug

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

myelofibrosis

Editor's Picks